169 related articles for article (PubMed ID: 19152710)
1. TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors.
Cheong JK; Gunaratnam L; Zang ZJ; Yang CM; Sun X; Nasr SL; Sim KG; Peh BK; Rashid SB; Bonventre JV; Salto-Tellez M; Hsu SI
J Transl Med; 2009 Jan; 7():8. PubMed ID: 19152710
[TBL] [Abstract][Full Text] [Related]
2. TRIP-Br: a novel family of PHD zinc finger- and bromodomain-interacting proteins that regulate the transcriptional activity of E2F-1/DP-1.
Hsu SI; Yang CM; Sim KG; Hentschel DM; O'Leary E; Bonventre JV
EMBO J; 2001 May; 20(9):2273-85. PubMed ID: 11331592
[TBL] [Abstract][Full Text] [Related]
3. The TRIP-Br family of transcriptional regulators is essential for the execution of cyclin E-mediated cell cycle progression.
Sim KG; Cheong JK; Hsu SI
Cell Cycle; 2006 May; 5(10):1111-5. PubMed ID: 16721052
[TBL] [Abstract][Full Text] [Related]
4. TRIP-Br links E2F to novel functions in the regulation of cyclin E expression during cell cycle progression and in the maintenance of genomic stability.
Sim KG; Zang Z; Yang CM; Bonventre JV; Hsu SI
Cell Cycle; 2004 Oct; 3(10):1296-304. PubMed ID: 15467469
[TBL] [Abstract][Full Text] [Related]
5. Exploiting the TRIP-Br family of cell cycle regulatory proteins as chemotherapeutic drug targets in human cancer.
Zang ZJ; Sim KG; Cheong JK; Yang CM; Yap CS; Hsu SI
Cancer Biol Ther; 2007 May; 6(5):712-8. PubMed ID: 17507796
[TBL] [Abstract][Full Text] [Related]
6. CRM1-mediated nuclear export is required for 26 S proteasome-dependent degradation of the TRIP-Br2 proto-oncoprotein.
Cheong JK; Gunaratnam L; Hsu SI
J Biol Chem; 2008 Apr; 283(17):11661-76. PubMed ID: 18316374
[TBL] [Abstract][Full Text] [Related]
7. Transcription regulator TRIP-Br2 mediates ER stress-induced brown adipocytes dysfunction.
Qiang G; Whang Kong H; Gil V; Liew CW
Sci Rep; 2017 Jan; 7():40215. PubMed ID: 28067333
[TBL] [Abstract][Full Text] [Related]
8. Identification of PP2A as a novel interactor and regulator of TRIP-Br1.
Zang ZJ; Gunaratnam L; Cheong JK; Lai LY; Hsiao LL; O'Leary E; Sun X; Salto-Tellez M; Bonventre JV; Hsu SI
Cell Signal; 2009 Jan; 21(1):34-42. PubMed ID: 18940248
[TBL] [Abstract][Full Text] [Related]
9. Role of PELP1/MNAR signaling in ovarian tumorigenesis.
Dimple C; Nair SS; Rajhans R; Pitcheswara PR; Liu J; Balasenthil S; Le XF; Burow ME; Auersperg N; Tekmal RR; Broaddus RR; Vadlamudi RK
Cancer Res; 2008 Jun; 68(12):4902-9. PubMed ID: 18559538
[TBL] [Abstract][Full Text] [Related]
10. CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation.
Hayashi R; Goto Y; Ikeda R; Yokoyama KK; Yoshida K
J Biol Chem; 2006 Nov; 281(47):35633-48. PubMed ID: 16984923
[TBL] [Abstract][Full Text] [Related]
11. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional and subcellular regulation of the TRIP-Br family.
Lai IL; Wang SY; Yao YL; Yang WM
Gene; 2007 Feb; 388(1-2):102-9. PubMed ID: 17141982
[TBL] [Abstract][Full Text] [Related]
13. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA
Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963
[TBL] [Abstract][Full Text] [Related]
14. EBF1-Mediated Upregulation of Ribosome Assembly Factor PNO1 Contributes to Cancer Progression by Negatively Regulating the p53 Signaling Pathway.
Shen A; Chen Y; Liu L; Huang Y; Chen H; Qi F; Lin J; Shen Z; Wu X; Wu M; Li Q; Qiu L; Yu N; Sferra TJ; Peng J
Cancer Res; 2019 May; 79(9):2257-2270. PubMed ID: 30862720
[TBL] [Abstract][Full Text] [Related]
15. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
16. The obesity-induced transcriptional regulator TRIP-Br2 mediates visceral fat endoplasmic reticulum stress-induced inflammation.
Qiang G; Kong HW; Fang D; McCann M; Yang X; Du G; Blüher M; Zhu J; Liew CW
Nat Commun; 2016 Apr; 7():11378. PubMed ID: 27109496
[TBL] [Abstract][Full Text] [Related]
17. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.
Conner EA; Lemmer ER; Omori M; Wirth PJ; Factor VM; Thorgeirsson SS
Oncogene; 2000 Oct; 19(44):5054-62. PubMed ID: 11042693
[TBL] [Abstract][Full Text] [Related]
18. SEI family of nuclear factors regulates p53-dependent transcriptional activation.
Watanabe-Fukunaga R; Iida S; Shimizu Y; Nagata S; Fukunaga R
Genes Cells; 2005 Aug; 10(8):851-60. PubMed ID: 16098148
[TBL] [Abstract][Full Text] [Related]
19. ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.
Shin HW; Choi H; So D; Kim YI; Cho K; Chung HJ; Lee KH; Chun YS; Cho CH; Kang GH; Kim WH; Park JW
Gastroenterology; 2014 Aug; 147(2):430-442.e8. PubMed ID: 24846398
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
